Sufficiency of CD40 activation and immune checkpoint blockade for T cell priming and tumor immunity (Q90660461)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:32213589 AND SRC:MED&resulttype=core&format=json

15 April 2020

title

Sufficiency of CD40 activation and immune checkpoint blockade for T cell priming and tumor immunity (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:32213589 AND SRC:MED&resulttype=core&format=json

15 April 2020

author name string

Alexander H Morrison

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:32213589 AND SRC:MED&resulttype=core&format=json

15 April 2020

Mark S Diamond

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:32213589 AND SRC:MED&resulttype=core&format=json

15 April 2020

Ceire A Hay

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:32213589 AND SRC:MED&resulttype=core&format=json

15 April 2020

Katelyn T Byrne

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:32213589 AND SRC:MED&resulttype=core&format=json

15 April 2020

Robert H Vonderheide

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:32213589 AND SRC:MED&resulttype=core&format=json

15 April 2020

publication date

25 March 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:32213589 AND SRC:MED&resulttype=core&format=json

Proceedings of the National Academy of Sciences of the United States of America

15 April 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:32213589 AND SRC:MED&resulttype=core&format=json

15 April 2020

volume

117

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:32213589 AND SRC:MED&resulttype=core&format=json

15 April 2020

issue

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:32213589 AND SRC:MED&resulttype=core&format=json

15 April 2020

page(s)

8022-8031

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:32213589 AND SRC:MED&resulttype=core&format=json

Approaching the asymptote? Evolution and revolution in immunology

15 April 2020

cites work

1 reference

12 December 2020

The immune responses in CD40-deficient mice: impaired immunoglobulin class switching and germinal center formation

1 reference

12 December 2020

Functional role of type I and type II interferons in antiviral defense

1 reference

12 December 2020

CD40 antibody evokes a cytotoxic T-cell response that eradicates lymphoma and bypasses T-cell help

1 reference

12 December 2020

CD40 activation in vivo overcomes peptide-induced peripheral cytotoxic T-lymphocyte tolerance and augments anti-tumor vaccine efficacy

1 reference

12 December 2020

Conversion of tumor-specific CD4 T-cell tolerance to T-cell priming through in vivo ligation of CD40

1 reference

12 December 2020

Cytotoxic T lymphocyte antigen-4 (CTLA-4) regulates primary and secondary peptide-specific CD4( ) T cell responses

1 reference

12 December 2020

CTLA-4 blockade reverses CD8 T cell tolerance to tumor by a CD4 T cell- and IL-2-dependent mechanism

1 reference

12 December 2020

T-cell immunodeficiency following cytotoxic antineoplastic therapy: a review

1 reference

12 December 2020

Innate immune recognition

1 reference

12 December 2020

CD40 stimulation leads to effective therapy of CD40(-) tumors through induction of strong systemic cytotoxic T lymphocyte immunity

1 reference

12 December 2020

Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: a double-blind, randomized, vehicle-controlled study

1 reference

12 December 2020

Anti-CD40 monoclonal antibody therapy in combination with irradiation results in a CD8 T-cell-dependent immunity to B-cell lymphoma

1 reference

12 December 2020

Synergy between chemotherapy and immunotherapy in the treatment of established murine solid tumors

1 reference

12 December 2020

PD-L1/B7H-1 inhibits the effector phase of tumor rejection by T cell receptor (TCR) transgenic CD8 T cells

1 reference

12 December 2020

Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice

1 reference

12 December 2020

Enhanced efficacy and reduced toxicity of multifactorial adjuvants compared with unitary adjuvants as cancer vaccines.

1 reference

12 December 2020

Treatment of vulvar intraepithelial neoplasia with topical imiquimod

1 reference

12 December 2020

Toll-like receptors activate innate and adaptive immunity by using dendritic cell-intrinsic and -extrinsic mechanisms

1 reference

12 December 2020

Batf3 Deficiency Reveals a Critical Role for CD8 Dendritic Cells in Cytotoxic T Cell Immunity

1 reference

12 December 2020

Randomized phase 2/3 trial of CpG oligodeoxynucleotide PF-3512676 alone or with dacarbazine for patients with unresectable stage III and IV melanoma.

1 reference

12 December 2020

Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodies

1 reference

12 December 2020

Optimized peptide vaccines eliciting extensive CD8 T-cell responses with therapeutic antitumor effects

1 reference

12 December 2020

Activation of human B cells by the agonist CD40 antibody CP-870,893 and augmentation with simultaneous toll-like receptor 9 stimulation

1 reference

12 December 2020

Intracerebral administration of CpG oligonucleotide for patients with recurrent glioblastoma: a phase II study

1 reference

12 December 2020

CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans

1 reference

12 December 2020

Programmed Death 1 Regulates Development of Central Memory CD8 T Cells after Acute Viral Infection

1 reference

12 December 2020

Randomized phase III trial of paclitaxel/carboplatin with or without PF-3512676 (Toll-like receptor 9 agonist) as first-line treatment for advanced non-small-cell lung cancer

1 reference

12 December 2020

MPYS is required for IFN response factor 3 activation and type I IFN production in the response of cultured phagocytes to bacterial second messengers cyclic-di-AMP and cyclic-di-GMP.

1 reference

12 December 2020

Post-chemotherapy T-cell recovery is a marker of improved survival in patients with advanced thoracic malignancies

1 reference

12 December 2020

Agonistic CD40 antibodies and cancer therapy

1 reference

12 December 2020

Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma

1 reference

12 December 2020

Parasite fate and involvement of infected cells in the induction of CD4 and CD8 T cell responses to Toxoplasma gondii

1 reference

12 December 2020

Radiation as immunomodulator: implications for dendritic cell-based immunotherapy

1 reference

12 December 2020

Diverse roles for T-bet in the effector responses required for resistance to infection.

1 reference

12 December 2020

Innate immune recognition of cancer

1 reference

12 December 2020

Induced PD-L1 expression mediates acquired resistance to agonistic anti-CD40 treatment

1 reference

12 December 2020

Induction of T-cell Immunity Overcomes Complete Resistance to PD-1 and CTLA-4 Blockade and Improves Survival in Pancreatic Carcinoma

1 reference

12 December 2020

Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer

1 reference

12 December 2020

Tumor-Promoting Desmoplasia Is Disrupted by Depleting FAP-Expressing Stromal Cells.

1 reference

12 December 2020

Flt3 Ligand Is Essential for Survival and Protective Immune Responses during Toxoplasmosis

1 reference

12 December 2020

Immunogenic Chemotherapy Sensitizes Tumors to Checkpoint Blockade Therapy

1 reference

12 December 2020

CD40 Stimulation Obviates Innate Sensors and Drives T Cell Immunity in Cancer

1 reference

12 December 2020

CpG-induced antitumor immunity requires IL-12 in expansion of effector cells and down-regulation of PD-1.

1 reference

12 December 2020

Agonistic CD40 mAb-Driven IL12 Reverses Resistance to Anti-PD1 in a T-cell-Rich Tumor.

1 reference

12 December 2020

Lack of immunoediting in murine pancreatic cancer reversed with neoantigen

1 reference

12 December 2020

Immunogenic cell death in cancer and infectious disease

1 reference

12 December 2020

Systemic Immunity Is Required for Effective Cancer Immunotherapy

1 reference

12 December 2020

T cell costimulatory receptor CD28 is a primary target for PD-1-mediated inhibition.

1 reference

12 December 2020

T-cell invigoration to tumour burden ratio associated with anti-PD-1 response.

1 reference

12 December 2020

Proliferation of PD-1 CD8 T cells in peripheral blood after PD-1-targeted therapy in lung cancer patients.

1 reference

12 December 2020

Vaccination with High-Affinity Epitopes Impairs Antitumor Efficacy by Increasing PD-1 Expression on CD8 T Cells

1 reference

12 December 2020

Intratumoral STING Activation with T-cell Checkpoint Modulation Generates Systemic Antitumor Immunity.

1 reference

12 December 2020

An immunogenic personal neoantigen vaccine for patients with melanoma

1 reference

12 December 2020

CD39 Expression Defines Cell Exhaustion in Tumor-Infiltrating CD8 T Cells.

1 reference

12 December 2020

High-dimensional single-cell analysis predicts response to anti-PD-1 immunotherapy

1 reference

12 December 2020

Cancer immunotherapy using checkpoint blockade.

1 reference

12 December 2020

Radiotherapy and CD40 Activation Separately Augment Immunity to Checkpoint Blockade in Cancer

1 reference

12 December 2020

Tumor Cell-Intrinsic Factors Underlie Heterogeneity of Immune Cell Infiltration and Response to Immunotherapy

1 reference

12 December 2020

TLR Stimulation during T-cell Activation Lowers PD-1 Expression on CD8 T Cells

1 reference

12 December 2020

Long-term outcomes of a phase I study of agonist CD40 antibody and CTLA-4 blockade in patients with metastatic melanoma

1 reference

12 December 2020

Successful Anti-PD-1 Cancer Immunotherapy Requires T Cell-Dendritic Cell Crosstalk Involving the Cytokines IFN-γ and IL-12

1 reference

12 December 2020

A CD40 Agonist and PD-1 Antagonist Antibody Reprogram the Microenvironment of Nonimmunogenic Tumors to Allow T-cell-Mediated Anticancer Activity

1 reference

12 December 2020

Distinct Immune Cell Populations Define Response to Anti-PD-1 Monotherapy and Anti-PD-1/Anti-CTLA-4 Combined Therapy

1 reference

12 December 2020

Tumor cell-intrinsic EPHA2 suppresses anti-tumor immunity by regulating PTGS2 (COX-2)

1 reference

12 December 2020

Clonal replacement of tumor-specific T cells following PD-1 blockade

1 reference

12 December 2020

CD40 Agonist Antibodies in Cancer Immunotherapy

1 reference

12 December 2020

Combination anti-CTLA-4 plus anti-PD-1 checkpoint blockade utilizes cellular mechanisms partially distinct from monotherapies

1 reference

12 December 2020